"The absence of benefits from intensive glucose lowering treatment further illustrates why relying on surrogate end points for treating people is a fallacy. Marketing new drugs based only on evidence that they decrease glucose or HbA1c plasma levels, or both, should not be allowed. Practitioners (and patients) should not rely on either blood glucose targets or HbA1c targets or the concept of “the lower the better.”
I BMJ denne uka er det mer om surrogatendepunktenes utilstrekkelighet ved sukkersyke. Vi må slutte å tenke jo lavere jo bedre om Hba1c og glukose?
http://www.bmj.com/content/343/bmj.d4169.full
Innlegg
Ingen kommentarer:
Legg inn en kommentar